Targeted In Vivo Delivery of Genetic Medicines Utilizing an Engineered Lentiviral Vector Platform Results in CAR T and NK Cell Generation

Investigators described the development of a lentiviral platform based on a novel, detargeted viral fusogen and a membrane-bound targeting moiety to enable in vivo targeted delivery of stably integrating genetic medicines without the need for lymphodepletion.